1. 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. (September 2015) Authors: Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroyakovskiy, D.; Lichinitser, M.; Dummer, R.; Grange, F.; Mortier, L.; Chiarion-Sileni, V.; Drucis, K.; Krajsova, I.; Hauschild, A.; Mookerjee, B.; Legos, J.; Schadendorf, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3323 The GERMELATOX DeCOG-trial: The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective. (September 2015) Authors: Kaehler, K.C.; Augustin, M.; Blohme, C.; Forschner, A.; Gutzmer, R.; Garbe, C.; Heinzerling, L.; Kornek, T.; Livingstone, E.; Loquai, C.; Maul, L.V.; Rudolph, B.; Schadendorf, D.; Stade, B.; Terheyden, P.; Gebhardt, C.; Wagner, T.; Hauschild, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study. (September 2015) Authors: Hansson, J.; Bartley, K.; Grob, J.J.; Kuntsfeld, R.; Dréno, B.; Mortier, L.; Ascierto, P.A.; Licitra, L.; Dutriaux, C.; Jouary, T.; Meyer, N.; Guillot, B.; Dummer, R.; Fife, K.; Ernst, D.S.; Yim, Y.M.; Williams, S.; Fittipaldo, A.; Basset-Seguin, N.; Hauschild, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3343 Exploratory analysis of vismodegib (VISMO) treatment discontinuation in the STEVIE study. (September 2015) Authors: Hauschild, A.; Hansson, J.; Grob, J.J.; Kunstfeld, R.; Dréno, B.; Mortier, L.; Ascierto, P.A.; Dummer, R.; Licitra, L.; Fife, K.; Ernst, D.S.; Dutriaux, C.; Jouary, T.; Meyer, N.; Guillot, B.; Williams, S.; Tandon, M.; Hou, J.; Basset-Seguin, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S681 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM). (September 2015) Authors: Grob, J.J.; Amonkar, M.; Karaszewska, B.; Schachter, J.; Dummer, R.; Mackiewicz, A.; Stroiakovski, D.; Drucis, K.; Grange, F.; Chiarion-Sileni, V.; Rutkowski, P.; Lichinitser, M.; Levchenko, E.; Wolter, P.; Hauschild, A.; Long, G.V.; Sun, P.; McDowell, D.O.; Mookerjee, B.; Robert, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences. (1st April 2021) Authors: Dessinioti, C.; Geller, A.C.; Stergiopoulou, A.; Dimou, N.; Lo, S.; Keim, U.; Gershenwald, J.E.; Haydu, L.E.; Dummer, R.; Mangana, J.; Hauschild, A.; Egberts, F.; Vieira, R.; Brinca, A.; Zalaudek, I.; Deinlein, T.; Evangelou, E.; Thompson, J.F.; Scolyer, R.A.; Peris, K. Journal: British journal of dermatology Issue: Volume 185:Number 1(2021) Page Start: 101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences. (1st July 2021) Authors: Dessinioti, C.; Geller, A.C.; Stergiopoulou, A.; Dimou, N.; Lo, S.; Keim, U.; Gershenwald, J.E.; Haydu, L.E.; Dummer, R.; Mangana, J.; Hauschild, A.; Egberts, F.; Vieira, R.; Brinca, A.; Zalaudek, I.; Deinlein, T.; Evangelou, E.; Thompson, J.F.; Scolyer, R.A.; Peris, K. Journal: British journal of dermatology Issue: Volume 185:Number 1(2021) Page Start: 101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF‐200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. (1st August 2018) Authors: Morton, C.A.; Dominicus, R.; Radny, P.; Dirschka, T.; Hauschild, A.; Reinhold, U.; Aschoff, R.; Ulrich, M.; Keohane, S.; Ekanayake‐Bohlig, S.; Ibbotson, S.; Ostendorf, R.; Berking, C.; Gröne, D.; Schulze, H.J.; Ockenfels, H.M.; Jasnoch, V.; Kurzen, H.; Sebastian, M.; Stege, H. Journal: British journal of dermatology Issue: Volume 179:Number 2(2018) Page Start: 309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF‐200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy3. (16th May 2018) Authors: Morton, C.A.; Dominicus, R.; Radny, P.; Dirschka, T.; Hauschild, A.; Reinhold, U.; Aschoff, R.; Ulrich, M.; Keohane, S.; Ekanayake‐Bohlig, S.; Ibbotson, S.; Ostendorf, R.; Berking, C.; Gröne, D.; Schulze, H.J.; Ockenfels, H.M.; Jasnoch, V.; Kurzen, H.; Sebastian, M.; Stege, H. Journal: British journal of dermatology Issue: Volume 179:Number 2(2018) Page Start: 309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. (November 2018) Authors: Kandolf Sekulovic, L.; Guo, J.; Agarwala, S.; Hauschild, A.; McArthur, G.; Cinat, G.; Wainstein, A.; Caglevic, C.; Lorigan, P.; Gogas, H.; Alvarez, M.; Duncombe, R.; Lebbe, C.; Peris, K.; Rutkowski, P.; Stratigos, A.; Forsea, A.-M.; De La Cruz Merino, L.; Kukushkina, M.; Dummer, R. Journal: European journal of cancer Issue: Volume 104(2018) Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗